Cardiovascular Risk and Mortality in Patients with Active and Treated Hypercortisolism

Overview

Journal Gland Surg

Publisher AME Publishing Company

Specialty Endocrinology

Date 2020 Mar 25

PMID 32206598

Citations 17

Authors

Dingfeng Li

Omar M El Kawkgi

Andres F Henriquez

Irina Bancos

Affiliations

Soon will be listed here.

Abstract

Patients with hypercortisolism demonstrate high cardiovascular morbidity and mortality, especially if diagnosis is delayed. Hypercortisolism-induced cardiovascular and metabolic comorbidities include hypertension, impaired glucose metabolism, dyslipidemia, and obesity. High prevalence of cardiovascular risk factors leads to increased rate of cardiovascular events and mortality. This risk is reduced, albeit not reversed even after successful treatment of hypercortisolism. In this review we will describe prevalence and mechanisms of cardiovascular comorbidities in patients with hypercortisolism. In addition, we will summarize the effect of therapy on cardiovascular risk factors, events, as well as mortality.

Citing Articles

Mousa Basha M, Al-Kassou B, Weber M, Beiert T, Bakhtiary F, Zimmer S Clin Res Cardiol. 2025; .

PMID: 39992388 DOI: 10.1007/s00392-025-02623-6.

Cardiovascular risk improvement after laparoscopic adrenalectomy in patients with cortisol-secreting adrenal adenoma, a retrospective cohort study.

Wonglhaw W, Santi-Ngamkun A, Ratchanon S, Usawachintachit M, Sowanthip D, Panumatrassamee K Gland Surg. 2024; 13(11):2128-2136.

PMID: 39678424 PMC: 11635579. DOI: 10.21037/gs-24-398.

Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study.

Kaminski K, Blatkiewicz M, Szyszka M, Olechnowicz A, Komarowska H, Klimont A Int J Mol Sci. 2024; 25(16).

PMID: 39201408 PMC: 11354279. DOI: 10.3390/ijms25168721.

Clinical Evaluation of Adrenal Incidentaloma: The Experience of a Referral Center.

Petramala L, Circosta F, Marino L, Palombi E, Costanzo M, Servello A Biomedicines. 2024; 12(8).

PMID: 39200374 PMC: 11351527. DOI: 10.3390/biomedicines12081910.

Management of Diabetes Mellitus in Acromegaly and Cushing's Disease with Focus on Pasireotide Therapy: A Narrative Review.

De Fano M, Falorni A, Malara M, Porcellati F, Fanelli C Diabetes Metab Syndr Obes. 2024; 17:2761-2774.

PMID: 39072348 PMC: 11283249. DOI: 10.2147/DMSO.S466328.

References

Klomjit N, Rowan D, Kattah A, Bancos I, Taler S . New-Onset Resistant Hypertension in a Newly Diagnosed Prostate Cancer Patient. Am J Hypertens. 2019; 32(12):1214-1217. DOI: 10.1093/ajh/hpz125. View

Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A . LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014; 99(4):1375-83. DOI: 10.1210/jc.2013-2117. View

Yasuda G, Shionoiri H, Umemura S, Takasaki I, Ishii M . Exaggerated blood pressure response to angiotensin II in patients with Cushing's syndrome due to adrenocortical adenoma. Eur J Endocrinol. 1994; 131(6):582-8. DOI: 10.1530/eje.0.1310582. View

Barahona M, Resmini E, Vilades D, Pons-Llado G, Leta R, Puig T . Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab. 2013; 98(3):1093-9. DOI: 10.1210/jc.2012-3547. View

Jeffcoate W, Rees L, TOMLIN S, Jones A, Edwards C, Besser G . Metyrapone in long-term management of Cushing's disease. Br Med J. 1977; 2(6081):215-7. PMC: 1631369. DOI: 10.1136/bmj.2.6081.215. View

Ntali G, Asimakopoulou A, Siamatras T, Komninos J, Vassiliadi D, Tzanela M . Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol. 2013; 169(5):715-23. DOI: 10.1530/EJE-13-0569. View

Di Dalmazi G, Pasquali R, Beuschlein F, Reincke M . Subclinical hypercortisolism: a state, a syndrome, or a disease?. Eur J Endocrinol. 2015; 173(4):M61-71. DOI: 10.1530/EJE-15-0272. View

Moncet D, Morando D, Pitoia F, Katz S, Rossi M, Bruno O . Ketoconazole therapy: an efficacious alternative to achieve eucortisolism in patients with Cushing's syndrome. Medicina (B Aires). 2007; 67(1):26-31. View

Graversen D, Vestergaard P, Stochholm K, Gravholt C, Jorgensen J . Mortality in Cushing's syndrome: a systematic review and meta-analysis. Eur J Intern Med. 2012; 23(3):278-82. DOI: 10.1016/j.ejim.2011.10.013. View

10.

Hirata F . Lipomodulin: a possible mediator of the action of glucocorticoids. Adv Prostaglandin Thromboxane Leukot Res. 1983; 11:73-8. View

11.

Lindholm J, Juul S, Jorgensen J, Astrup J, Bjerre P, Feldt-Rasmussen U . Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86(1):117-23. DOI: 10.1210/jcem.86.1.7093. View

12.

Valassi E, Santos A, Yaneva M, Toth M, Strasburger C, Chanson P . The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol. 2011; 165(3):383-92. DOI: 10.1530/EJE-11-0272. View

13.

Steffensen C, Bak A, Rubeck K, Jorgensen J . Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010; 92 Suppl 1:1-5. DOI: 10.1159/000314297. View

14.

Toja P, Branzi G, Ciambellotti F, Radaelli P, De Martin M, Lonati L . Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure. Clin Endocrinol (Oxf). 2011; 76(3):332-8. DOI: 10.1111/j.1365-2265.2011.04206.x. View

15.

Terzolo M, Allasino B, Pia A, Peraga G, Daffara F, Laino F . Surgical remission of Cushing's syndrome reduces cardiovascular risk. Eur J Endocrinol. 2014; 171(1):127-36. DOI: 10.1530/EJE-13-0555. View

16.

Ragnarsson O, Olsson D, Papakokkinou E, Chantzichristos D, Dahlqvist P, Segerstedt E . Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. J Clin Endocrinol Metab. 2019; 104(6):2375-2384. DOI: 10.1210/jc.2018-02524. View

17.

Bailey M, Mullins J, Kenyon C . Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome. Hypertension. 2009; 54(4):890-6. DOI: 10.1161/HYPERTENSIONAHA.109.134973. View

18.

Clayton R, Raskauskiene D, Reulen R, Jones P . Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab. 2011; 96(3):632-42. DOI: 10.1210/jc.2010-1942. View

19.

Nieman L, Biller B, Findling J, Newell-Price J, Savage M, Stewart P . The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008; 93(5):1526-40. PMC: 2386281. DOI: 10.1210/jc.2008-0125. View

20.

Stewart P, Walker B, Holder G, OHalloran D, Shackleton C . 11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab. 1995; 80(12):3617-20. DOI: 10.1210/jcem.80.12.8530609. View